These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 999321)

  • 1. Autoantibodies in vitiligo.
    Betterle C; Del Prete GF; Peserico A; Bersani G; Caracciolo F; Trisotto A; Poggi F
    Arch Dermatol; 1976 Sep; 112(9):1328. PubMed ID: 999321
    [No Abstract]   [Full Text] [Related]  

  • 2. [Autoantibodies in vitiligo. Clinical significance].
    Morgan M; Castells A; Ramírez A
    Med Cutan Ibero Lat Am; 1986; 14(2):139-42. PubMed ID: 3528710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autoantibody responses to melanocytes in the depigmenting skin disease vitiligo.
    Kemp EH; Gavalas NG; Gawkrodger DJ; Weetman AP
    Autoimmun Rev; 2007 Jan; 6(3):138-42. PubMed ID: 17289548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Autoantibodies in vitiligo].
    Herz KC
    Med Klin; 1978 Oct; 73(43):3. PubMed ID: 713958
    [No Abstract]   [Full Text] [Related]  

  • 5. Identification of peptides specific for antibodies in vitiligo using a phage library.
    Jadali Z; Eslami MB; Sanati MH; Mansouri P; Mahmoudi M; Maghsoudi N; Esfahanian F
    Clin Exp Dermatol; 2005 Nov; 30(6):694-701. PubMed ID: 16197391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitiligo and antibodies to melanocytes.
    Bystryn JC; Pfeffer S
    Prog Clin Biol Res; 1988; 256():195-206. PubMed ID: 3285350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vitiligo and polyglandular autoimmune disease with autoantibodies to melanin-producing cells. A new syndrome?
    Peserico A; Rigon F; Semenzato G; Caretto A; Pasini CV; Betterle C
    Arch Dermatol; 1981 Nov; 117(11):751-2. PubMed ID: 7316541
    [No Abstract]   [Full Text] [Related]  

  • 8. Congenital stable symmetrical type vitiligo in a patient whose mother developed vitiligo during pregnancy.
    Kedward AL; Gawkrodger DJ
    Eur J Dermatol; 2008; 18(3):353. PubMed ID: 18515208
    [No Abstract]   [Full Text] [Related]  

  • 9. Reactivity to tyrosinase: expression in cancer (melanoma) and autoimmunity (vitiligo).
    Merimsky O; Shoenfeld Y; Baharav E; Zigelman R; Fishman P
    Hum Antibodies Hybridomas; 1996; 7(4):151-6. PubMed ID: 9140726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vitiligo--an autoimmune side-effect of intravesical bacillus Calmette-Guérin instillation?
    Beisland C; Holsen DS
    Scand J Urol Nephrol; 2004; 38(2):182-3. PubMed ID: 15204415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-thyroid peroxidase antibody and vitiligo: a controlled study.
    Daneshpazhooh M; Mostofizadeh G M; Behjati J; Akhyani M; Robati RM
    BMC Dermatol; 2006 Mar; 6():3. PubMed ID: 16526964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoimmunity as an aetiological factor in vitiligo.
    Rezaei N; Gavalas NG; Weetman AP; Kemp EH
    J Eur Acad Dermatol Venereol; 2007 Aug; 21(7):865-76. PubMed ID: 17658994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complement-fixing activity to melanin-producing cells preceding the onset of vitiligo in a patient with type 1 polyglandular failure.
    Betterle C; Caretto A; Pedini B; Rigon F; Bertoli P; Peserico A
    Arch Dermatol; 1992 Jan; 128(1):123-4. PubMed ID: 1739282
    [No Abstract]   [Full Text] [Related]  

  • 14. [Melanocyte antibodies in idiopathic vitiligo (author's transl)].
    Höfs T; Zugehör M; Morenz J
    Dermatol Monatsschr; 1981 Nov; 167(11):685-92. PubMed ID: 7044847
    [No Abstract]   [Full Text] [Related]  

  • 15. [Characterization of antigens reacting with vitiligo and cytoplasmic melanoma antibodies].
    Presser HJ; Morenz J; Höfs T; Zugehör M; Kühne KH; Brödemann M
    Dermatol Monatsschr; 1987; 173(8):441-5. PubMed ID: 3311840
    [No Abstract]   [Full Text] [Related]  

  • 16. Apoptosis of melanocytes in vitiligo results from antibody penetration.
    Ruiz-Argüelles A; Brito GJ; Reyes-Izquierdo P; Pérez-Romano B; Sánchez-Sosa S
    J Autoimmun; 2007 Dec; 29(4):281-6. PubMed ID: 17888626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune mechanisms in vitiligo.
    Bystryn JC
    Immunol Ser; 1989; 46():447-73. PubMed ID: 2488866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Vitiligo and other endocrine complications with an autoimmune basis].
    Herrera Pombo JL; Rodríguez ME; Rovira A; Martínez J; Salvador ML; Pérez Naranjo JM; de Castro A; Orbaneja JG
    Rev Clin Esp; 1982 Dec; 167(5):321-5. PubMed ID: 6897748
    [No Abstract]   [Full Text] [Related]  

  • 19. [Immunological changes in common vitiligo].
    Vignale R; Paciel J; Calandria L
    Med Cutan Ibero Lat Am; 1988; 16(4):343-7. PubMed ID: 3068448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mapping of melanin-concentrating hormone receptor 1 B cell epitopes predicts two major binding sites for vitiligo patient autoantibodies.
    Gavalas NG; Gottumukkala RV; Gawkrodger DJ; Watson PF; Weetman AP; Kemp EH
    Exp Dermatol; 2009 May; 18(5):454-63. PubMed ID: 19320743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.